2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1753

Response Gene to Complement-32 Promotes Plasma Cell Differentiation and Enhances Lupus-like Chronic Graft Versus Host Disease
Abstract Number: 1754

BANK1 Controls the Development of SLE By Modulating TLR7 Signaling and Type I IFN-Induced Translation Initiation Pathway in B Cells
Abstract Number: 1755

The Lymphotoxin/Megakaryoblastic Leukemia 1/Actin Axis As a Master Regulator of TLR Signaling in Lupus
Abstract Number: 1756

The Oxidative Burst Mediates Anti-Inflammatory Clearance of Dead Cells in a Mouse Model of SLE and Inflammatory Arthritis
Abstract Number: 1757

Absence of Estrogen Receptor Alpha Is Protective Against Nephrotoxic Serum-Induced Nephritis
Abstract Number: 1758

Alterations in Nuclear Structure Promote Lupus Autoimmunity in a Mouse Model
Abstract Number: 1759

Activation of T-Follicular Helper Cells and B Cells in Ultraviolet Light-Induced Murine Model of Systemic Lupus Erythematosus
Abstract Number: 1760

PD-1 Signaling Interferes with OX40 to Alter the Suppressive Function and Proliferation of CD4+ Regulatory T Cells in Lupus Mice
Abstract Number: 1762

Reciprocal Roles of Intestinal Microbiota in the Pathogenesis of Organ-Specific Autoimmune Diseases in a Lymphopenia-Induced Autoimmunity Mouse Model
Abstract Number: 1763

Neutrophil Netosis Formation during the UVB Induced-Skin Inflammation
Abstract Number: 1764

Type 1 Interferon in the Skin Stimulated By Ultraviolet B Light Generates Immune Suppression Mediated By Idoleamine 2,3-Dioxygenase 1
Abstract Number: 1765

MiR155 Deficient Mice Show Reduced Disease Severity in Pristane-Induced Lupus
Abstract Number: 1766

HPV Vaccination of Nzbxw/F1 Mice
Abstract Number: 1767

Noninvasive Assessment of Macrophage Activation in Experimental Glomerulonephritis Using Optical Imaging with Near-Infrared Light Serves As a Surrogate of Disease Activity
Abstract Number: 1768

Improved Tissue Clearing and 2-Photon Imaging of Mouse Kidneys Reveals Immune Cell Architecture in Nephrotoxic Nephritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].